CD274 and glioblastoma: Various clinical studies targeting PD-1/PD-L1 and CTLA-4 have been carried out in patients with GBM to promote powerful antitumor immune responses (Fong et al., 2012; Litak et al., 2019; Liu F. et al., 2020).